1. IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL. (June 2017) Authors: Cramer, P.; Demirkan, F.; Fraser, G.; Pristupa, A.; Bartlett, N.; Dilhuydy, M.; Loscertales, J.; Avigdor, A.; Rule, S.; Samoilova, O.; Goy, A.; Ganguly, S.; Poggesi, I.; Lavezzi, S.M.; De Nicolao, G.; de Jong, J.; Neyens, M.; Salman, M.; Howes, A.; Mahler, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS. (June 2017) Authors: Kipps, T.J.; Fraser, G.; Coutre, S.E.; Brown, J.R.; Barrientos, J.C.; Barr, P.M.; Byrd, J.C.; O'Brien, S.M.; Dilhuydy, M.; Hillmen, P.; Jaeger, U.; Moreno, C.; Cramer, P.; Stilgenbauer, S.; Chanan‐Khan, A.A.; Mahler, M.; Salman, M.; Cheng, M.; Londhe, A.; Ninomoto, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗